Roche Portfolio Fit InterMune's pirfenidone (Esbriet) has been part of Roche's portfolio since 2014, with established EU/Canada approvals and ongoing US Phase 3 activity, enabling cross-sell, co-promotion, and geographic expansion under Roche's global network.

US Regulatory Path The Phase 3 program aimed at US regulatory registration signals strong potential for US commercialization partnerships, licensing deals, or joint development arrangements to accelerate market access and revenue.

Orphan Pulmonology Niche A focused focus on IPF and orphan fibrotic diseases targets a high-need segment, offering opportunities to explore additional indications or disease-specific partnerships within Roche's ecosystem.

Lean Commercial Size With revenue in the range of 50-100 million and a lean 51-200 employee base, InterMune is well positioned for targeted deals, licenses, or pilot collaborations that can scale within Roche's platform.

Global Market Expansion Esbriet’s footprint in EU and Canada provides a blueprint for expanding into the US and other regions through licensing or co-promotion, leveraging Roche’s regulatory and payer relationships to speed market access.